Phospholipase A2 receptor membranous nephropathy; This literature-non-study case was reported in a literature article and describes the occurrence of GLOMERULONEPHRITIS MEMBRANOUS (Phospholipase A2 receptor membranous nephropathy) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Glomerulonephritis membranous.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced GLOMERULONEPHRITIS MEMBRANOUS (Phospholipase A2 receptor membranous nephropathy) (seriousness criterion medically significant). The patient was treated with OBINUTUZUMAB for Membranous nephropathy, at an unspecified dose and frequency. At the time of the report, GLOMERULONEPHRITIS MEMBRANOUS (Phospholipase A2 receptor membranous nephropathy) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood albumin: 2.7g/dl Laboratories during presentation was 2.7g/dl. On an unknown date, Blood creatinine: 1.7 mg/dl Baseline 1.7 mg/dl and 2.1 g/dl Laboratories during last follow up was 2.1 g/dl. On an unknown date, Protein urine: 16.6 g/d Laboratories during presentation was 16.6 g/d. On an unknown date, Red blood cells urine: than (<) 3 / high power field (hpf) Laboratories during presentation was less than (<) 3 /HPF.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered GLOMERULONEPHRITIS MEMBRANOUS (Phospholipase A2 receptor membranous nephropathy) to be possibly related.    This article reports a case series of patients who developed new or relapsing GN post vaccination.   This patient developed relapse of GN post Moderna COVID-19 vaccination. Patient presented with symptom of edema Duration of remission before relapse was 8 months.  Concomitant medications were not reported  This is a literature non study case concerning a 70-year-old, male patient with medical history of previous membranous nephropathy, who experienced the unexpected serious (medically significant) event of relapsed Phospholipase A2 receptor membranous nephropathy. The event occurred approximately 4 weeks after the second dose of Spikevax with unknown information regarding the first dose. Patient presented with edema and was diagnosed with a relapsed membranous nephropathy and received Obinutuzumab with no further information regarding the follow up. The rechallenge is not applicable. Patient´s medical history of previous membranous nephropathy is a confounder for the event. Patient was in remission for 8 months before relapse. The benefit-risk relationship of Spikevax is not affected by this report.   This case was linked to MOD-2021-357261, MOD-2021-357609, MOD-2021-357610, MOD-2021-357611, MOD-2021-357612, MOD-2021-357614.   Most recent FOLLOW-UP information incorporated above includes: On 20-Oct-2021: Follow up received by safety 21-Oct-2021 included an Email with Agency received from team and does not contain any new information; Sender's Comments: This is a literature non study case concerning a 70-year-old, male patient with medical history of previous membranous nephropathy, who experienced the unexpected serious (medically significant) event of relapsed Phospholipase A2 receptor membranous nephropathy. The event occurred approximately 4 weeks after the second dose of Spikevax with unknown information regarding the first dose. Patient presented with edema and was diagnosed with a relapsed membranous nephropathy and received Obinutuzumab with no further information regarding the follow up. The rechallenge is not applicable. Patient´s medical history of previous membranous nephropathy is a confounder for the event. Patient was in remission for 8 months before relapse. The benefit-risk relationship of Spikevax is not affected by this report.